Lyell Immunopharma (LYEL) Net Margin (2020 - 2026)
Lyell Immunopharma recorded quarterly Net Margin of 2103350.0% in Q1 2026, down 0.99% quarter-over-quarter from 2082800.0% in Q4 2025, and down 133899286.0% year-over-year from N/an in Q1 2025.
Lyell Immunopharma's Net Margin history runs 7 years deep, the most recent figure standing at 2103350.0% for Q1 2026.
- In Q1 2026, Net Margin fell 133899286.0% year-over-year to 2103350.0%; the TTM figure through Mar 2026 stood at 789954.84% (down 26774561.0% YoY), while the FY2025 annual figure was 712011.11%, down 16334390.0% from the prior year.
- Net Margin came in at 2103350.0% for Q1 2026 at Lyell Immunopharma, down from 2082800.0% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 23.42% in Q4 2022 to a low of 2139533.33% in Q3 2022.
- A 5-year average of 746575.0% and a median of 347415.38% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin plunged 213775871 bps in 2022 and surged 192980933 bps in 2023, its largest moves.
- Lyell Immunopharma's Net Margin stood at 23.42% in 2022, then tumbled by 1721920 bps to 403261.54% in 2023, then tumbled by 342 bps to 1783881.82% in 2024, then fell by 17 bps to 2082800.0% in 2025, then retreated by 1 bps to 2103350.0% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 2103350.0%, 2082800.0%, and 226580.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -2,103,350.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,103,350.00% |
| Dec 31, 2025 | -2,082,800.00% |
| Sep 30, 2025 | -226,580.00% |
| Jun 30, 2025 | -548,300.00% |
| Mar 31, 2025 | -764,357.14% |
| Dec 31, 2024 | -1,783,881.82% |
| Sep 30, 2024 | -131,000.00% |
| Jun 30, 2024 | -347,415.38% |
| Mar 31, 2024 | -1,625,200.00% |
| Dec 31, 2023 | -403,261.54% |
| Sep 30, 2023 | -209,724.00% |
| Jun 30, 2023 | -224,596.30% |
| Mar 31, 2023 | -89,321.54% |
| Dec 31, 2022 | -23.42% |
| Sep 30, 2022 | -2,139,533.33% |
| Jun 30, 2022 | -101.59% |
| Mar 31, 2022 | -12,328.93% |
| Dec 31, 2021 | -1,673.10% |
| Sep 30, 2021 | -1,774.63% |
| Jun 30, 2021 | -2,377.82% |
| Mar 31, 2021 | -2,250.14% |
| Dec 31, 2020 | -1,682.66% |
| Sep 30, 2020 | -3,340.84% |
| Jun 30, 2020 | -3,229.15% |